ADRB3

Beta-3 adrenergic receptor · P13945 · ADRB3 on Sugi Atlas →

202,434 patent compounds predicted against ADRB3, 132,872 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Salmeterol (SCHEMBL4767)	1.00	17/20
Salmeterol (SCHEMBL4768)	1.00	17/20
Xamoterol (SCHEMBL64461)	1.00	17/20
Salmeterol (SCHEMBL18070)	0.76	17/20
Protokylol (SCHEMBL50567)	0.76	13/20
Labetalol (SCHEMBL41230)	1.00	12/20
Labetalol (SCHEMBL4582)	0.98	11/20
Labetalol (SCHEMBL41231)	0.98	11/20
Lisadimate (SCHEMBL62520)	0.66	11/20
SCHEMBL3391	0.64	10/20
Croconazole (SCHEMBL34369)	0.53	10/20
Croconazole (SCHEMBL36790)	0.52	10/20
SCHEMBL51473	0.48	8/20
SCHEMBL15736	0.46	8/20
Carazolol (SCHEMBL77901)	0.65	7/20
Carazolol (SCHEMBL77903)	0.65	7/20
Sulfinalol (SCHEMBL78008)	0.56	7/20
SCHEMBL43535	0.54	7/20
Propranolol (SCHEMBL3955)	1.00	6/20
Levopropranolol (SCHEMBL3956)	1.00	6/20

Clinical trials — most relevant to ADRB3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences	PHASE4	RECRUITING
Vibegron for ENergy Thinking and Resilience in Aging	PHASE3	NOT_YET_RECRUITING
A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure	PHASE3	COMPLETED
Beta 3 Agonist Treatment in Heart Failure-2	PHASE2/PHASE3	COMPLETED
Effect of Esmolol on Oxygenation Index in Patients With Acute Respiratory Distress Syndrome	PHASE3	RECRUITING
Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan	PHASE3	UNKNOWN
Mechanisms for Activation of Beige Adipose Tissue in Humans	PHASE2	RECRUITING
Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer	PHASE2	NOT_YET_RECRUITING
Mirabegron For Erectile Dysfunction	PHASE1/PHASE2	COMPLETED
Study of Orofacial Pain and PropRANOlol	PHASE2	COMPLETED
Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure	PHASE2	COMPLETED
Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue	PHASE2	COMPLETED
Does Mirabegron Increase the Body Heat Generated by the Nervous System	EARLY_PHASE1	COMPLETED
Activation of Brown Adipose Tissue Metabolism Using Mirabegron	nan	COMPLETED
Effect of Time-restricted Eating on Catecholamine-sensitivity of Adipose Tissue in Obese Adults	nan	ACTIVE_NOT_RECRUITING
Influence of Nebivolol on Postmenopausal Women	nan	UNKNOWN
Genetic Influences of Albuterol Response In Children With Bronchiolitis	nan	COMPLETED
Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity	nan	RECRUITING
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients	nan	COMPLETED
Renal Denervation in Patients With Chronic Heart Failure	nan	WITHDRAWN
Influence of Genetic Polymorphisms on Ventricular Structure and Function in Patients With Single Ventricle Anatomy	nan	COMPLETED
Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms	nan	COMPLETED
Can Caudal Dexmedetomidine Provide Effective Analgesia?	nan	NOT_YET_RECRUITING
Genetic Determinants of Response to Beta Blockade	nan	COMPLETED
Influence of Diabetic Neuropathy on Activation of Brown Adipose Tissue	nan	UNKNOWN
Brain Receptors in Sympathetic Nervous System Regulation	nan	COMPLETED
Beta-Blockers on Neoadjuvant Immunochemotherapy for Hypertensive Patients With Gastric Cancer	nan	ACTIVE_NOT_RECRUITING
The Locus Coeruleus, Norepinephrine and Cognitive Aging	nan	ACTIVE_NOT_RECRUITING
Effects of Chronic Use of Doxazosin in Men With Benign Prostatic Hyperplasia	nan	COMPLETED
Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ADRB3 binder may also engage these)

Protein	Name	Similarity
Q9XT57	—	1.000	Q9XT57 →
Q9XT58	—	1.000	Q9XT58 →
Q28524	—	1.000	Q28524 →
Q95252	—	1.000	Q95252 →
P46626	—	1.000	P46626 →
Q60483	—	1.000	Q60483 →
O02662	—	1.000	O02662 →
Q9TST4	—	1.000	Q9TST4 →
HTR6	5-hydroxytryptamine receptor 6	0.996	landscape →
P25962	—	0.996	P25962 →
P26255	—	0.993	P26255 →
P34971	—	0.991	P34971 →
Q9R1C8	—	0.991	Q9R1C8 →
P51436	—	0.989	P51436 →
P30729	—	0.988	P30729 →
GALR2	Galanin receptor type 2	0.988	landscape →
P31388	—	0.988	P31388 →
Q5IS65	—	0.988	Q5IS65 →
KISS1R	KiSS-1 receptor	0.985	landscape →
Q924U1	—	0.985	Q924U1 →
Q9TT96	—	0.985	Q9TT96 →
Q7TQN7	—	0.984	Q7TQN7 →
Q80UC6	—	0.983	Q80UC6 →
P79148	—	0.983	P79148 →
DRD4	D(4) dopamine receptor	0.983	landscape →
P31387	—	0.983	P31387 →
Q91V45	—	0.983	Q91V45 →
Q28998	—	0.983	Q28998 →
Q7TQP2	—	0.982	Q7TQP2 →
P47899	—	0.982	P47899 →